Connect with Us
602 Park Point Drive, Suite 225, Golden, CO 80401 – +1 303.495.2073
© 2025 Medical Affairs Professional Society (MAPS). All Rights Reserved Worldwide.
Anna Walz
Anna Walz is a 25+ year veteran in the pharmaceutical industry. She is the Founder and CEO Emeritus of MedEvoke, a MEDISTRAVA Company (Medical Division of Huntsworth). MedEvoke is a global medical consulting firm dedicated to working with Medical Affairs leaders to drive alignment through development of clear medical strategies that can be globally communicated, measured, and analyzed. This has, for the first time, enabled Medial Affairs to track the impact of internal efforts on the external scientific and digital exchanges.
Anna currently serves as Senior Strategic Advisor to MEDISTRAVA and provides professional guidance on the formation of a cross-company Medical Analytics Function that will overlay the community of medical affairs agencies within the healthcare division of Huntsworth. Her external responsibilities include working with key clients and professional organizations on market implementation and validation of the medical analytics function. Internal responsibilities include providing input on annual strategy planning process and relevant roll-out workstreams. Anna also serves of the Board of Directors for Healios AG, a Swiss-based medical device software manufacturer that is dedicated to finding solutions in clinical research and patient monitoring through innovative digital technologies.
Anna, who often speaks on the topics of medical strategy, launch excellence, impact metrics for medical affairs, female entrepreneurship, and diversity in the biosciences, is also a regular guest-lecturer on the topic of Pharmacology & Drug Marketing at the Rutgers Medical School. In addition to speaking, Anna has a keen interest in her own continuing education and is a graduate of both the Tuck-WBENC Executive Education program and the Entrepreneurial Master’s Program (EMP), a joint collaboration of the Entrepreneurs’ Organization (EO) and the Massachusetts Institute of Technology (MIT).
Anna has been one of the most vocal champions for MAPS since its inception, has served as Co-Chair of the Standards & Guidance Committee, and is currently serving on the organization’s Board of Directors and on the Fund Development Committee.
Iris Loew-Friedrich
Prof. Dr. med. Iris Loew-Friedrich is Chief Medical Officer for UCB, a member of the company’s Executive Committee and Head of Development Solutions. She provides strategic global leadership for world-wide clinical development, medical affairs, regulatory affairs, statistical innovation, real world evidence, patient safety/pharmacovigilance and quality assurance. Iris started her service for patients in the pharmaceutical industry in 1992 with a focus on clinical development in the areas of immunology, bone disease and neurology, delivering together with her teams several novel medicines to patients. She held various positions in Research and Development in different companies, always with a focus on global drug development. Since 2001, prior to joining UCB, Iris was the Global Head of Research and Development at Schwarz Pharma (acquired by UCB in 2006) and a member of their Executive Committee. Iris is a physician, board-certified in internal medicine, with a medical license from the University of Frankfurt where she also holds a visiting professorship at the Medical School. Iris is active in industry associations, a member of different supervisory boards, including the board of TransCelerate and PhRMA Foundation. She is passionate about making a difference to the lives of people living with severe diseases.
AMEET NATHWANI
A U.K. citizen, born in Uganda and educated in the U.K., Dr Nathwani qualified in medicine in 1987 in London, acquired his specialization in Cardiology at a number of University Hospitals in London, and has a diploma in Pharmaceutical Medicine and an executive Masters in Business Administration.
Dr. Nathwani has more than 20 years of experience in the pharmaceutical industry beginning in 1994 when he joined Glaxo Group Research. From the period of 1994 to 2004 he held increasingly senior global functional and franchise leadership roles in research and development in Glaxo, SmithKline Beecham and GlaxoSmithKline, both in Europe and the US. He joined Novartis in 2004 as the Senior Vice President and Global Development Head of the Cardiovascular and Metabolic Franchise and over the period of 11 years has held a number of senior development and commercial positions including the Global Head of the Critical Care Business Franchise. He was appointed as Global Head of Medical Affairs Novartis Pharma AG in June 2014 and became an extended member of the Pharma Executive Committee where he led the establishment of a Real World Evidence Center of Excellence and Digital Medicine capability.
He was appointed Chief Medical Officer in May 2016 and Chief Digital Officer in February 2019.
Krishna Bahadursingh
Dr Krishna Bahadursingh joined Syneos Health in Tokyo, Japan, as Regional Vice President, Medical APAC/Japan on July 1st. His main responsibility would be to build out the Medical Affairs function to capitalize on the available opportunities and for Syneos in Japan/Asia Pacific.
He joined the pharma industry from clinical practice, working for both Japanese headquartered and MNC companies and spent more than two decades in multi- disciplinary, thought- leadership roles central to ensuring patient safety and regulatory compliance as well as spearheading evolution in the medical affairs function from a support organization to a value-added one fully dedicated to delivering favorable reported outcomes for both patients and their families.
Krishna has resided primarily in Tokyo, Japan for the past 20 years but has also lived or worked in a number of countries in Asia. In addition to his medical qualifications and experience he is a Fellow of the Royal College of Surgeons (FRCS), Fellow of the of the Faculty of Pharmaceutical Medicine (FFPM), holds an Executive MBA and is also an attorney-at-law (LLB). He is a member of the Association of Medical Doctors in Asia AMDA).
Cezary Statuch
Dr Cezary Statuch joined Biogen in January 2015 and is currently the Vice President of Medical for the region of International Markets. His career in the pharmaceutical industry spans almost 30 years. During his professional life Cezary has held positions in clinical research operations, global drug development and medical affairs. Prior to joining Biogen, Cezary led the China Research and Development team for Bristol-Myers Squibb. He was involved in managing activities in China for almost 15 years, 7 of which he spent living in Shanghai. Cezary is actively engaged in the training and education of physicians in the healthcare industry across many emerging and established markets. He is a founding member of the China Medical Affairs Network. He is also a member of the Executive Committee of the Medical Affairs Professional Society. Cezary is passionate about promoting access to medicines across Emerging Markets to address unmet medical needs and help patients to prevail against serious medical conditions.
KAREN WOOLLEY
Karen is the Global Lead for Patient Partnerships at Envision Pharma Group and oversees staff in Envision’s Tokyo and Sydney offices. She has 30 years of experience in the healthcare sector, gained in academia, hospital, industry (Pfizer, Johnson & Johnson), and agency (ProScribe Medical Communications, Envision Pharma Group) environments, in North America and the Asia Pacific region.  Karen has a strong focus on strategic initiatives in the medical affairs sector and has led international teams to conduct and publish research on publications ethics and on patient engagement and involvement in industry-sponsored research.  Karen is a Professor at two universities and has been a government-appointed director overseeing 6 hospitals, serving on the Patient Safety and Quality Committee, and managing a $2B budget. She was the inaugural chair of the Asia Pacific Advisory Committee for the International Society of Medical Publication Professionals, is an Honorary Fellow of the American Medical Writers Association, a Life Member of the Australasian Society of Clinical and Regulatory Scientists (ARCS), an Editorial Board Member for the Research Integrity and Peer Review journal, and is the only author from the Asia Pacific region on the international Good Publication Practice for Communicating Company-Sponsored Research (GPP3) guidelines and the Joint Position Statement on the Role of Professional Medical Writers. Karen is regularly invited to present her research and share her insights at major international and regional conferences.
ZHIHUI (ZIG) LANG
Dr. Lang is the Senior Vice President and Head of Medical Affairs and Pharmacovigilance at Bayer Healthcare China including Hong Kong. In this role, Dr. Lang directs the Medical Affairs, Medical Science Liaisons, Medical Communications, Scientific Operations, Medical Compliance, Patient Support and Disease Management Programs, Health Economics and Outcome Research and Pharmacovigilance.
Prior to coming to Bayer China, Dr. Lang worked in Bayer’s Global Medical Affairs Oncology in the United States. Dr. Lang has over 18 years of pharmaceutical industry experiences ranging from early and late stage clinical development to medical affairs. Dr. Lang held positions with increasing responsibilities at Endo Pharmaceuticals, Johnson and Johnson, Wyeth and Novo Nordisk. Dr. Lang is a board-certified oncologist and hematologist. He received his medical education at the Fourth Military Medical University in Xi’an and PhD in Biochemistry at Rush University in Chicago.